All In Biotech

Drug Trial Radar · NCT05166889

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (OBERON)

Last checked: Nov 20, 2026Latest source record: Apr 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,132 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,132

Actual

Start

Jan 3, 2022

Primary completion

Jan 19, 2026

Study completion Mar 11, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Dec 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12 months. Participants should be receiving optimised treatment with maintenance inhaled therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) in stable doses throughout at least 3 months prior to enrolment.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

  • TozorakimabDrug

    Administered subcutaneously tozorakimab Dose 1 and placebo through Week 52.

  • TozorakimabDrug

    Administered subcutaneously tozorakimab Dose 2 through Week 52.

  • PlaceboDrug

    Placebo administered subcutaneously, equivalent volume to tozorakimab through week 52.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized rate of moderate to severe COPD exacerbations in participants who are former smokers.Time frame: over 52 weeks

Locations

212 sites in 21 countries. Site status is shown where the registry gives one.

  • Research Site

    Huntsville, Alabama

  • Research Site

    Mobile, Alabama

  • Research Site

    Montgomery, Alabama

  • Research Site

    Phoenix, Arizona

  • Research Site

    Bakersfield, California

  • Research Site

    Sacramento, California

  • Research Site

    Boynton Beach, Florida

  • Research Site

    Ormond Beach, Florida

  • Research Site

    Plantation, Florida

  • Research Site

    Meridian, Idaho

  • Research Site

    Evergreen Park, Illinois

  • Research Site

    Normal, Illinois

  • Research Site

    Iowa City, Iowa

  • Research Site

    Kansas City, Kansas

  • Research Site

    Baton Rouge, Louisiana

  • Research Site

    Zachary, Louisiana

  • Research Site

    Baltimore, Maryland

  • Research Site

    Rochester, Minnesota

  • Research Site

    St Louis, Missouri

  • Research Site

    Missoula, Montana

  • Research Site

    Brick, New Jersey

  • Research Site

    New York, New York

  • Research Site

    The Bronx, New York

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Durham, North Carolina

  • Research Site

    Gastonia, North Carolina

  • Research Site

    Fargo, North Dakota

  • Research Site

    DuBois, Pennsylvania

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    Sayre, Pennsylvania

  • Research Site

    Rapid City, South Dakota

  • Research Site

    Franklin, Tennessee

  • Research Site

    Houston, Texas

  • Research Site

    Kingwood, Texas

  • Research Site

    Salt Lake City, Utah

  • Research Site

    Burlington, Vermont

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    CABA, Argentina

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    Córdoba, Argentina

Showing 40 of 212 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.